Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and POMP or Dasatinib, Prednisone, and Blinatumomab in Older Patients With ALL
NCT02143414Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2015
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Started Jun 2015; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02143414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143414.